- Previous Close
1.6400 - Open
2.0000 - Bid --
- Ask --
- Day's Range
2.0000 - 3.2000 - 52 Week Range
1.4340 - 4.4400 - Volume
1,031,772 - Avg. Volume
27,881 - Market Cap (intraday)
132.475M - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0600 - Earnings Date Sep 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
www.inventivapharma.comRecent News: IVA.PA
View More
Performance Overview: IVA.PA
Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVA.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVA.PA
View MoreValuation Measures
Market Cap
85.87M
Enterprise Value
96.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.28
Price/Book (mrq)
--
Enterprise Value/Revenue
6.17
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
19.27M
Net Income Avi to Common (ttm)
-104.19M
Diluted EPS (ttm)
-2.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: IVA.PA
View MoreCompany Insights: IVA.PA
IVA.PA does not have Company Insights